HCM News and Press, HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for ORPATHYS ®  (savolitinib) has been granted conditional approval b...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (E...

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements &#x...

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies&#x...

2026-05-28 18:15:03 ET from Morgan Stanley issued a price target of $13.60 for HCM on 2026-05-28 20:19:29. The adjusted price target was set to $13.60. At the time of the announcement, HCM was trading at $11.23. The overall price target consensus is at $17.50 with high p...

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinic...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“ Innovent ”, HKEX:1801) today jointly announce that the New Drug Application (NDA) for the c...

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held April 28 th  are now available for online vie...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with warm ...

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, April 28, 2026 featuring live webcast presentations from international companies with American Depositary Receipt (ADR)...